title: Antihypertensive response to combination of olmesartan and amlodipine does not depend on method and time of drug administration.
abstract: Fixed combinations of antihypertensive drugs have the potentiality to improve blood pressure (BP) control. However, when pharmacokinetic parameters of the two drugs are different, both method and time of administration of the two drugs may modify the antihypertensive response. In an open-label, single-blind, randomized study we compared antihypertensive effect of four administration schemes of a combination therapy of olmesartan and amlodipine in the same group of hypertensive patients, using ambulatory blood pressure monitoring (ABPM). The olmesartan + amlodipine combination has demonstrated to provide a good control of BP, with systolic and diastolic BP constantly below 130 and 85 mmHg over the 24 h. The simultaneous or separate administration of the 2 drugs fully overlapped, suggesting that the fixed combination and the separate administration induce a similar and sustained BP control.
authors: Department of Clinical Medicine, Cardiovascular and Immunological Sciences, Federico II University Hospital, via S. Pansini 5, 80131, Naples, Italy.
authors: Francesco
authors: F
authors: Rozza
authors: Valentina
authors: V
authors: Trimarco
authors: Raffaele
authors: R
authors: Izzo
authors: Mario
authors: M
authors: Santoro
authors: Maria Virginia
authors: MV
authors: Manzi
authors: Marina
authors: M
authors: Marino
authors: Gianfranco
authors: G
authors: Di Renzo
authors: Bruno
authors: B
authors: Trimarco
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017311:Amlodipine / Q000008:administration & dosage / Q000493:pharmacokinetics; D000704:Analysis of Variance; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000493:pharmacokinetics; D001794:Blood Pressure / Q000187:drug effects; D018660:Blood Pressure Monitoring, Ambulatory; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000493:pharmacokinetics; D016009:Chi-Square Distribution; D002940:Circadian Rhythm; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D007093:Imidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics; D007558:Italy; D055118:Medication Adherence; D009010:Monte Carlo Method; D016037:Single-Blind Method; D013777:Tetrazoles / Q000008:administration & dosage / Q000493:pharmacokinetics; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D017311:Amlodipine; D047228:Angiotensin II Type 1 Receptor Blockers; D002121:Calcium Channel Blockers; D004338:Drug Combinations; D007004:Hypoglycemic Agents; D007093:Imidazoles; C437965:olmesartan; D013777:Tetrazoles
references: Am J Hypertens. 1999 Aug;12(8 Pt 2):73S-79S
references: 10478700
references: Clin Ther. 2008 Apr;30(4):587-604
references: 18498909
references: BMJ. 2003 Jun 28;326(7404):1427
references: 12829555
references: Circulation. 2000 Sep 26;102(13):1536-41
references: 11004145
references: Hypertension. 2000 Nov;36(5):901-6
references: 11082164
references: Lancet. 2005 Sep 10-16;366(9489):895-906
references: 16154016
references: Diabetes Care. 2009 May;32(5):845-50
references: 19223610
references: Hypertension. 1992 Jan;19(1):93-101
references: 1730444
references: Circulation. 2009 Oct 20;120(16):1598-605
references: 19805653
references: J Hypertens. 1993 Oct;11(10):1133-7
references: 8258679
references: J Am Soc Hypertens. 2010 Mar-Apr;4(2):90-8
references: 20400053
references: Fundam Clin Pharmacol. 2009 Dec;23(6):767-74
references: 19659504
references: J Clin Hypertens (Greenwich). 2009 Jul;11(7):376-82
references: 19583634
references: J Hypertens. 2005 Jul;23(7):1417-23
references: 15942466
references: Vasc Health Risk Manag. 2011;7:183-92
references: 21490944
references: N Engl J Med. 2008 Dec 4;359(23):2417-28
references: 19052124
references: J Clin Hypertens (Greenwich). 2006 Dec;8(12):865-72
references: 17170612
references: Ann Intern Med. 2001 Nov 6;135(9):825-34
references: 11694107
references: N Engl J Med. 2010 Apr 29;362(17):1575-85
references: 20228401
references: Med Care. 2010 May;48(5):418-25
references: 20393367
references: Clin Drug Investig. 2003;23(7):419-30
references: 17535053
references: Am J Med. 2004 Jul 1;117(1):14-8
references: 15210383
references: Hypertension. 2010 Jul;56(1):99-104
references: 20497990
references: Hypertension. 1999 Aug;34(2):267-72
references: 10454452
references: J Hypertens Suppl. 2001 Jun;19(1):S3-14
references: 11451212
references: J Hypertens. 2003 Nov;21(11):1983-92
references: 14597836
references: Eur J Pharmacol. 1995 Oct 16;285(2):181-8
references: 8566137
references: J Hypertens. 2007 Jun;25(6):1105-87
references: 17563527
references: Drugs. 2007;67(9):1309-27
references: 17547473
references: J Cardiovasc Pharmacol. 2009 Nov;54(5):427-36
references: 19730391
references: High Blood Press Cardiovasc Prev. 2008 Oct;15(4):283-310
references: 23355131
references: J Hypertens. 2012 Jun;30(6):1065-74
references: 22573073
references: J Hypertens Suppl. 1996 Sep;14(2):S61-6; discussion S66-8
references: 8934380
references: J Hypertens. 2001 Nov;19(11):1981-9
references: 11677363
references: Clin Chem. 1972 Jun;18(6):499-502
references: 4337382
references: Lancet. 2004 Jun 19;363(9426):2022-31
references: 15207952
references: J Hypertens. 2009 Nov;27(11):2121-58
references: 19838131
references: Clin Drug Investig. 2009;29(1):11-25
references: 19067471
references: Clin Pharmacol Ther. 1992 Oct;52(4):378-83
references: 1330398
references: JAMA. 2003 May 21;289(19):2560-72
references: 12748199
references: Clin Drug Investig. 2009;29(7):427-439
references: 19499960
references: J Hypertens. 1987 Feb;5(1):93-8
references: 3584967
references: Arch Intern Med. 1992 Sep;152(9):1855-60
references: 1387782
references: J Clin Hypertens (Greenwich). 2010 Jan;12(1):40-6
references: 20047629